{"filing":{"accession_number":"0001213900-26-065850","cik":"0001739174","ticker":"PHGE","company_name":"BiomX Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"ea0293750-8k_biomx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1739174/000121390026065850/ea0293750-8k_biomx.htm"},"events":[{"id":6557,"run_id":5739,"accession_number":"0001213900-26-065850","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"BiomX issued 1,013,637 restricted shares of common stock upon partial conversion of a convertible promissory note from Mandragola Ltd., with the shares issued in reliance on Section 4(a)(2) of the Securities Act without registration. This is a classic unregistered equity issuance tied to debt conversion, representing dilution to existing shareholders. The concurrent warrant grant (2,000,000 shares at $12.00 exercise price) further evidences the dilutive financing structure. Item 3.02 disclosure and the explicit reliance on Section 4(a)(2) exemption confirm this is a material unregistered sale of equity securities.","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":[{"id":4874,"accession_number":"0001213900-26-065850","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BiomX issued 1,013,637 restricted shares of common stock upon partial conversion of a convertible promissory note from Mandragola Ltd., with the shares issued in reliance on Section 4(a)(2) of the Securities Act without registration. This is a classic unregistered equity issuance tied to debt conversion, representing dilution to existing shareholders. The concurrent warrant grant (2,000,000 shares at $12.00 exercise price) further evidences the dilutive financing structure. Item 3.02 disclosure and the explicit reliance on Section 4(a)(2) exemption confirm this is a material unregistered sale of equity securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:33:34.651044+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4874,"accession_number":"0001213900-26-065850","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"BiomX issued 1,013,637 restricted shares of common stock upon partial conversion of a convertible promissory note from Mandragola Ltd., with the shares issued in reliance on Section 4(a)(2) of the Securities Act without registration. This is a classic unregistered equity issuance tied to debt conversion, representing dilution to existing shareholders. The concurrent warrant grant (2,000,000 shares at $12.00 exercise price) further evidences the dilutive financing structure. Item 3.02 disclosure and the explicit reliance on Section 4(a)(2) exemption confirm this is a material unregistered sale of equity securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:33:34.651044+00:00","company_name":"BiomX Inc.","ticker":"PHGE","filing_date":"2026-06-05"}]}